Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02202746
Title A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Clovis Oncology, Inc.
Indications

breast cancer

Therapies

Lucitanib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST